| 16.86 0.01 (0.06%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 20.3 | 1-year : | 20.72 |
| Resists | First : | 17.38 | Second : | 17.73 |
| Pivot price | 16.87 |
|||
| Supports | First : | 16.79 | Second : | 13.97 |
| MAs | MA(5) : | 16.86 | MA(20) : | 16.9 |
| MA(100) : | 16.3 |
MA(250) : | 16.35 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 24.5 |
D(3) : | 22.4 |
| RSI | RSI(14): 50.5 |
|||
| 52-week | High : | 21.03 | Low : | 10.82 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TBPH ] has closed above bottom band by 41.0%. Bollinger Bands are 90.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 16.9 - 16.96 | 16.96 - 17.01 |
| Low: | 16.68 - 16.76 | 16.76 - 16.82 |
| Close: | 16.74 - 16.86 | 16.86 - 16.96 |
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Fri, 31 Jul 2026
Theravance Biopharma Inc (TBPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Thu, 30 Jul 2026
Theravance Biopharma Inc (TBPH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Wed, 29 Jul 2026
TBPH|Theravance Biopharma Inc|Price:16.865|Chg%:-0.025 - TradingKey
Wed, 29 Jul 2026
Theravance Biopharma Inc (TBPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mon, 29 Jun 2026
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 98.3 (%) |
| Shares Short | 4,310 (K) |
| Shares Short P.Month | 4,780 (K) |
| EPS | 2.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.63 |
| Profit Margin | 104.3 % |
| Operating Margin | -33.1 % |
| Return on Assets (ttm) | 0.7 % |
| Return on Equity (ttm) | 50.1 % |
| Qtrly Rev. Growth | 15 % |
| Gross Profit (p.s.) | 1.5 |
| Sales Per Share | 2.11 |
| EBITDA (p.s.) | 0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 269 (M) |
| Levered Free Cash Flow | 23 (M) |
| PE Ratio | 7.56 |
| PEG Ratio | 0 |
| Price to Book value | 2.98 |
| Price to Sales | 7.96 |
| Price to Cash Flow | 3.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|